Kailera Therapeutics, Inc. went public at $16.00 a share
It sold 39,062,500 shares on Nasdaq Global Select Market under the ticker KLRA and raised $625.0 million before costs.
Final prospectus (424B4) filed April 17, 2026
The terms
-
Offered
39,062,500 shares
Checked
Source
“We are offering 39,062,500 shares of our common stock.”
A model read this, and code confirmed the quote appears in the filing. -
Price per share
$16.00
Checked
Source
“The public offering price is $16.00 per share.”
A model read this, and code confirmed the quote appears in the filing. -
Raised
$625,000,000before fees and costs
Checked
Source and check
Shares × price = 39,062,500 × $16.00 = $625,000,000. They match.
“Public offering price | $16.00 | $625,000,000”
A model read this, and code confirmed the quote appears in the filing. -
Bank fee
$43,750,000$1.12 a share, 7.0% of the raise
Checked
Source
“Underwriting discount and commissions(1) | $1.12 | $43,750,000”
A model read this, and code confirmed the quote appears in the filing. -
Lead banks
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI
From the prospectus
Source
“Joint Book-Running Managers J.P. Morgan | Jefferies | Leerink Partners | TD Cowen | Evercore ISI”
A model read this, and code confirmed the quote appears in the filing. -
Trades as
KLRA on Nasdaq Global Select Market
Checked
Source
“Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “KLRA.””
A model read this, and code confirmed the quote appears in the filing. -
Extra for the banks
Up to 5,859,375 sharesan option the banks may use
From the prospectus
Source
“We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to 5,859,375 additional shares of common stock from us at the initial public offering price, less the underwriting discounts and commissions.”
A model read this, and code confirmed the quote appears in the filing. - Final prospectus filed April 17, 2026
Not investment advice.Open the filing on SEC.gov
Who owns the company after the IPO
From the prospectus 39,062,500 of 123,677,939 shares outstanding after the offering (31.6%).
Where Kailera Therapeutics, Inc. sits among the last 12 months
Each bubble is one IPO. Bigger and higher means more money raised. The scale grows by ten times at each line.
New to these terms? How to read an IPO.